WAS
FPRX

WESPAC Advisors SoCal’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

WESPAC Advisors SoCal’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-300
Closed -$5K – 273
2018
Q1 		$5K Hold
300
– – ﹤0.01% 227
2017
Q4 		$6K Hold
300
– – ﹤0.01% 212
2017
Q3 		$12K Hold
300
– – 0.01% 196
2017
Q2 		$9K Hold
300
– – 0.01% 192
2017
Q1 		$10.8K Hold
300
– – 0.01% 184
2016
Q4 		$15K Hold
300
– – 0.01% 168
2016
Q3 		$15.7K Hold
300
– – 0.01% 164
2016
Q2 		$12.4K Buy
+300
New +$13K 0.01% 188

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WESPAC Advisors SoCal's FPRX Position: Q2 2018 in Review

WESPAC Advisors SoCal sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2018, closing a stake of 300 shares — an estimated $5K sold.

WESPAC Advisors SoCal first reported a position in FPRX in Q2 2016 and held it in 8 quarters. The position peaked at $15.7K in Q3 2016. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2018.

  • WESPAC Advisors SoCal reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • WESPAC Advisors SoCal sold 300 Five Prime Therapeutics, Inc. shares in Q2 2018, an estimated $5K.
  • WESPAC Advisors SoCal first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 8 quarters.
  • WESPAC Advisors SoCal's Five Prime Therapeutics, Inc. position peaked at $15.7K in Q3 2016.
  • 123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2018.

Based on WESPAC Advisors SoCal's 13F filing for Q2 2018, filed 13 Jul 2018.